Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NRXP NRX Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: NRXP
Price (delayed)
$2.45
Market cap
$42.36M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.01
Enterprise value
$45.21M
Big Rock Partners is a blank check company formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination
Highlights
NRX Pharmaceuticals's quick ratio has soared by 143% from the previous quarter and by 143% YoY
NRXP's EPS is up by 37% year-on-year and by 15% since the previous quarter
The company's equity has shrunk by 67% YoY and by 8% QoQ
NRX Pharmaceuticals's debt has increased by 28% from the previous quarter and by 24% YoY
Sector: Healthcare
Industry: Biotechnology
Key stats
What are the main financial stats of NRXP
Market
Valuations
Earnings
Shares outstanding
17.29M
Market cap
$42.36M
Enterprise value
$45.21M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$16.35M
Net income
-$24.11M
EBIT
-$24.11M
EBITDA
-$24.11M
Free cash flow
-$10.45M
Per share
Balance sheet
Liquidity
EPS
-$2.01
EPS diluted
-$2.01
Free cash flow per share
-$0.64
Book value per share
-$1.49
Revenue per share
$0
TBVPS
$0.46
Total assets
$7.59M
Total liabilities
$32.75M
Debt
$8.4M
Equity
-$25.16M
Working capital
-$25.5M
Debt to equity
-0.33
Current ratio
0.22
Quick ratio
0.17
Net debt/EBITDA
-0.12
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-460%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NRXP stock price
How has the NRX Pharmaceuticals stock price performed over time
Intraday
2.08%
1 week
20.1%
1 month
26.94%
1 year
-30.4%
YTD
11.36%
QTD
19.51%
Financial performance
How have NRX Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$16.35M
Net income
-$24.11M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 33% YoY and by 12% from the previous quarter
NRX Pharmaceuticals's net income has increased by 6% YoY and by 4% from the previous quarter
Price vs fundamentals
How does NRXP's price correlate with its fundamentals
Growth
What is NRX Pharmaceuticals's growth rate over time
Valuation
What is NRX Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NRXP's EPS is up by 37% year-on-year and by 15% since the previous quarter
The company's equity has shrunk by 67% YoY and by 8% QoQ
Efficiency
How efficient is NRX Pharmaceuticals business performance
NRX Pharmaceuticals's ROA has plunged by 97% YoY but it has increased by 21% from the previous quarter
Dividends
What is NRXP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NRXP.
Financial health
How did NRX Pharmaceuticals financials performed over time
The total assets is 77% less than the total liabilities
NRX Pharmaceuticals's quick ratio has soared by 143% from the previous quarter and by 143% YoY
The total assets has soared by 108% from the previous quarter and by 100% YoY
NRX Pharmaceuticals's debt is 133% more than its equity
The company's equity has shrunk by 67% YoY and by 8% QoQ
NRX Pharmaceuticals's debt has increased by 28% from the previous quarter and by 24% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.